Literature DB >> 25503966

Genetic testing and interpretive complexity: a BRCA1 gene mutation example.

D S Gogarty1, M P Farrell2, D J Gallagher2.   

Abstract

Diagnosis and interpretation of hereditary breast cancer can be a complex and challenging dilemma. Advances in genetic testing have resulted in guidelines for clinical evaluation and recommendations. Here, we present a case of one family with multiple cases of early-onset breast cancer, some due to a familial BRCA1 mutation but others unrelated to this pathogenic E143X nonsense mutation. In this case report, we highlight the complexities associated with adhering strictly to guidelines and highlight the need for clinical experience in when to deviate from recommended protocols.

Entities:  

Keywords:  BRCA; Breast; Cancer; E143X; Hereditary

Mesh:

Substances:

Year:  2014        PMID: 25503966     DOI: 10.1007/s11845-014-1238-5

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  8 in total

1.  Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.

Authors:  Kelly Metcalfe; Jan Lubinski; Henry T Lynch; Parviz Ghadirian; William D Foulkes; Charmaine Kim-Sing; Susan Neuhausen; Nadine Tung; Barry Rosen; Jacek Gronwald; Peter Ainsworth; Kevin Sweet; Andrea Eisen; Ping Sun; Steven A Narod
Journal:  J Natl Cancer Inst       Date:  2010-11-23       Impact factor: 13.506

2.  Family history and the risk of breast cancer: a systematic review and meta-analysis.

Authors:  P D Pharoah; N E Day; S Duffy; D F Easton; B A Ponder
Journal:  Int J Cancer       Date:  1997-05-29       Impact factor: 7.396

3.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Authors:  A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton
Journal:  Am J Hum Genet       Date:  2003-04-03       Impact factor: 11.025

4.  Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.

Authors:  Noah D Kauff; Nandita Mitra; Mark E Robson; Karen E Hurley; Shaokun Chuai; Deborah Goldfrank; Eve Wadsworth; Johanna Lee; Tessa Cigler; Patrick I Borgen; Larry Norton; Richard R Barakat; Kenneth Offit
Journal:  J Natl Cancer Inst       Date:  2005-09-21       Impact factor: 13.506

Review 5.  Cancer susceptibility and the functions of BRCA1 and BRCA2.

Authors:  Ashok R Venkitaraman
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

Review 6.  Familial breast cancer.

Authors:  F Lalloo; D G Evans
Journal:  Clin Genet       Date:  2012-04-13       Impact factor: 4.438

Review 7.  Counseling for male BRCA mutation carriers: a review.

Authors:  Hussain B Mohamad; Justus P Apffelstaedt
Journal:  Breast       Date:  2008-07-26       Impact factor: 4.380

8.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Authors:  Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-06-08       Impact factor: 157.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.